Abstract
Thyroid cancer (TC) has become one of most common endocrine malignancies in recent decades. Due to gene background polymorphism, it's outcome goes quite differently in each patient. For exploring the mechanism, we performed whole transcriptome sequencing of paired papillary thyroid carcinoma (PTC) and adjacent thyroid tissues. As a result, scavenger receptor class A member 5 (SCARA5) might be a crucial anti‐oncogene associated with PTC. By RT‐qPCR, we first detected the expression of SCARA5 in PTC tissue and three type of TC cell lines. Besides, The Cancer Genome Atlas (TCGA) data were gathered to analysis the relationship between SCARA5 and clinical feature. A series of loss‐function experiments in TC cell lines (KTC‐1 and BCPAP) to investigate the function of SCARA5 in PTC. The results showed that SCARA5 expression in PTC was lower than adjacent normal tissue. And, it's consistent with the TCGA database. After analyse the correlation between SCARA5 expression and clinicopathological features in TCGA database, we discovered that downregulated SCARA5 is significantly connected age (P = .04) and tumour size (P = .032). Knockdown of SCARA5 in TC cell line could significantly increase the function of cells proliferation, colony formation, migration, and invasion. Furthermore, we also proved that SCARA5 could modulate the expression of epithelial‐mesenchymal transition‐related proteins, which influence invasion and migration. To best of our knowledge, SCARA5 is a suppressor gene which was associated with PTC and might be a potential therapeutic target in the future.Significance of the studyThyroid cancer (TC) has become one of most common endocrine malignancies in recent decades. By whole transcriptome sequencing of paired papillary thyroid carcinoma (PTC) and adjacent thyroid tissues, author discovered that scavenger receptor class A member 5 (SCARA5) might be crucial anti‐oncogene associated with PTC. Furthermore, knocking‐down of SCARA5 in TC cell line can increase the function of cells proliferation, colony formation, migration, and invasion. Author also proved that SCARA5 could modulate the expression of epithelial‐mesenchymal transition‐related proteins.
Highlights
Thyroid cancer (TC) has become one of most frequent malignancies of the endocrine system in recent decades.[1]
TC is generally classified into four different histological types, including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma, and medullary thyroid carcinoma.[4]
We identified that scavenger receptor class A member 5 (SCARA5) act as an anti-oncogene involved in PTC tumorigenesis
Summary
Thyroid cancer (TC) has become one of most frequent malignancies of the endocrine system in recent decades.[1]. In human hepatocellular carcinoma (HCC), Huang et al found that SCARA5 expression have been down-regulated because of promoter hypermethylation and loss of heterozygosity; suppression of SCARA5 was correlates with cellular invasion and overall progression.[26] A considerable report noted that up-regulation of SCARA5 could inhibit lung cancer lines tumorigenesis and progression in vitro.[27] Ying Liu et al testified that inhibition of SCARA5 could promote tumorigenicity, colony formation, cell invasion and metastasis in oral squamous cell carcinoma.[28] Emerging shreds of evidence have manifested that SCARA5 act as effective anti-tumour gene in many tumour, whether the SCARA5 gene have essential role in PTC still remains unclear. With the help of sequencing technology, we have been revealed whole transcriptome bioinformation of 19 pairs PTC samples and its adjacent normal thyroid tissues.[29] The results showed that SCARA5 might act as a vital anti-tumour gene in the PTC. SCARA5 is a suppressor gene which was associated with PTC and might be a potential biomarker in the future
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
